Fig. 5
From: Effects of early local administration of high-dose bFGF on a recurrent laryngeal nerve injury model
A Representative microscopy images of double staining with cholinergic receptor nicotinic beta 1 subunit (CHRNB1) and synaptophysin in the untreated side (400 × magnification). White arrows indicate CHRNB1+ acetylcholine receptor or synaptophysin+, and yellow arrows indicate CHRNB1+/synaptophysin+ neuromuscular junction (NMJ). B Representative microscopy images of the NMJ on days 7 and 56 after high-dose basic fibroblast growth factor (bFGF) injection in the paralyzed side or saline injection in the paralyzed or non-paralyzed side (400 × magnification). White arrows indicate CHRNB1+ acetylcholine receptor, and yellow arrows indicate CHRNB1+/synaptophysin+ NMJ. C Temporal changes in the paralyzed/non-paralyzed ratio of the acetylcholine receptor after bFGF or saline injection in the paralyzed side. D Temporal changes in paralyzed/non-paralyzed ratio of NMJ after bFGF injection in the paralyzed side or saline injection in the paralyzed side. Error bars represent standard deviation. *P < .05 and **P < .01, Tukey’s multiple comparisons test. Saline group NPS, non-paralyzed side of the saline group; Saline group PS, paralyzed side of the saline group; High-dose group, paralyzed side of the high-dose basic fibroblast growth factor group